MedTrace Logo

Clinical Outcome of Intra Articular Injection of Autologous Platelet Rich Plasma in Anterior Cruciate Ligament Injury.

NCT07185802 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2025-09-22

No results posted yet for this study

Summary

This clinical trial will evaluate the effectiveness of platelet-rich plasma (PRP) injections for patients with anterior cruciate ligament (ACL) injury. ACL injuries commonly cause knee instability, pain, and reduced function, and rehabilitation alone may not fully restore recovery in all patients. PRP is prepared from a small sample of the patient's own blood and contains natural growth factors that may promote healing and improve joint function.

In this study, participants will be randomly assigned to one of two groups. The experimental group will receive a single ultrasound-guided injection of PRP into the knee joint along with a standard rehabilitation program. The control group will receive the rehabilitation program alone.

Participants will be followed up at 3 weeks, 8 weeks, and 16 weeks after treatment. At each follow-up visit, knee function, pain level, and physical performance will be assessed using validated outcome measures. The primary aim is to determine whether PRP provides additional benefit compared with rehabilitation alone in improving function and reducing symptoms in ACL-injured patients.

This study will provide new evidence about the role of PRP in ACL management, which may help guide future treatment decisions.

Conditions

  • Anterior Cruciate Ligament

Interventions

BIOLOGICAL

PRP injection

Ultrasound guided intraarticular PRP is given to the patient with partial ACL tear

OTHER

conventional conservative method (physical therapy, functional bracing, lifestyle modification)

conventional conservative method (physical therapy, functional bracing, lifestyle modification)

Sponsors & Collaborators

  • Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

    lead OTHER

Principal Investigators

  • Dr. Isfath Fauzia, MBBS · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

  • Prof. Dr. Md. Ali Emran, MBBS, FCPS · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

  • Dr. Md. Nuruzzaman Khandaker, MBBS, FCPS · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

  • Dr. Md. Tariqul Islam, MBBS, FCPS · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-27
Primary Completion
2026-04-30
Completion
2026-08-26

Countries

  • Bangladesh

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07185802 on ClinicalTrials.gov